Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2009;189:85–110. doi: 10.1007/978-3-540-79086-0_4

Viral Protease Inhibitors

Jeffrey Anderson 2, Celia Schiffer 2, Sook-Kyung Lee 3, Ronald Swanstrom 3,✉
Editors: Hans-Georg Kräusslich*, Ralf Bartenschlager*
PMCID: PMC7120715  PMID: 19048198

Abstract

This review provides an overview of the development of viral protease inhibitors as antiviral drugs. We concentrate on HIV-1 protease inhibitors, as these have made the most significant advances in the recent past. Thus, we discuss the biochemistry of HIV-1 protease, inhibitor development, clinical use of inhibitors, and evolution of resistance. Since many different viruses encode essential proteases, it is possible to envision the development of a potent protease inhibitor for other viruses if the processing site sequence and the catalytic mechanism are known. At this time, interest in developing inhibitors is limited to viruses that cause chronic disease, viruses that have the potential to cause large-scale epidemics, or viruses that are sufficiently ubiquitous that treating an acute infection would be beneficial even if the infection was ultimately self-limiting. Protease inhibitor development is most advanced for hepatitis C virus (HCV), and we also provide a review of HCV NS3/4A serine protease inhibitor development, including combination therapy and resistance. Finally, we discuss other viral proteases as potential drug targets, including those from Dengue virus, cytomegalovirus, rhinovirus, and coronavirus.

Keywords: Severe Acute Respiratory Syndrome, Severe Acute Respiratory Syndrome Coronavirus, Viral Protease Inhibitor, Substrate Envelope

Contributor Information

Hans-Georg Kräusslich, Email: hans-georg_kraeusslich@med.uni-heidelberg.de.

Ralf Bartenschlager, Email: ralf_bartenschlager@med.uni-heidelberg.de.

Ronald Swanstrom, Email: risunc@med.unc.edu.

References

  1. Allaire M, Chernaia MM, Malcolm BA, James MN. Picornaviral 3C cysteine proteinases have a fold similar to chymotrypsin-like serine proteinases. Nature. 1994;369:72–76. doi: 10.1038/369072a0. [DOI] [PubMed] [Google Scholar]
  2. Altman MD, Nalivaika EA, Prabu-Jeyabalan M, Schiffer CA, Tidor B. Computational design and experimental study of tighter binding peptides to an inactivated mutant of HIV-1 protease. Proteins. 2008;70:678–694. doi: 10.1002/prot.21514. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Anand K, Palm GJ, Mesters JR, Siddell SG, Ziebuhr J, Hilgenfeld R. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain. EMBO J. 2002;21:3213–3224. doi: 10.1093/emboj/cdf327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science. 2003;300:1763–1767. doi: 10.1126/science.1085658. [DOI] [PubMed] [Google Scholar]
  5. Arias CF, Preugschat F, Strauss JH. Dengue 2 virus NS2B and NS3 form a stable complex that can cleave NS3 within the helicase domain. Virology. 1993;193:888–899. doi: 10.1006/viro.1993.1198. [DOI] [PubMed] [Google Scholar]
  6. Bartenschlager R. The NS3/4A proteinase of the hepatitis C virus: unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy. J Viral Hepat. 1999;6:165–181. doi: 10.1046/j.1365-2893.1999.00152.x. [DOI] [PubMed] [Google Scholar]
  7. Binford SL, Weady PT, Maldonado F, Brothers MA, Matthews DA, Patick AK. In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother. 2007;51:4366–4373. doi: 10.1128/AAC.00905-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Brignole EJ, Gibson W. Enzymatic activities of human cytomegalovirus maturational protease assemblin and its precursor (pPR, pUL80a) are comparable: [corrected] maximal activity of pPR requires self-interaction through its scaffolding domain. J Virol. 2007;81:4091–4103. doi: 10.1128/JVI.02821-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cahn P, Villacian J, Lazzarin A, Katlama C, Grinsztejn B, Arasteh K, Lopez P, Clumeck N, Gerstoft J, Stavrianeas N, Moreno S, Antunes F, Neubacher D, Mayers D. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis. 2006;43:1347–1356. doi: 10.1086/508352. [DOI] [PubMed] [Google Scholar]
  10. Carrillo A, Stewart KD, Sham HL, Norbeck DW, Kohlbrenner WE, Leonard JM, Kempf DJ, Molla A. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J Virol. 1998;72:7532–7541. doi: 10.1128/jvi.72.9.7532-7541.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Chambers TJ, Nestorowicz A, Amberg SM, Rice CM. Mutagenesis of the yellow fever virus NS2B protein: effects on proteolytic processing, NS2B-NS3 complex formation, and viral replication. J Virol. 1993;67:6797–6807. doi: 10.1128/jvi.67.11.6797-6807.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Chellappan S, Kiran Kumar Reddy GS, Ali A, Nalam MN, Anjum SG, Cao H, Kairys V, Fernandes MX, Altman MD, Tidor B, Rana TM, Schiffer CA, Gilson MK. Design of mutationresistant HIV protease inhibitors with the substrate envelope hypothesis. Chem Biol Drug Des. 2007;69:455. doi: 10.1111/j.1747-0285.2007.00532.x. [DOI] [PubMed] [Google Scholar]
  13. Chen P, Tsuge H, Almassy RJ, Gribskov CL, Katoh S, Vanderpool DL, Margosiak SA, Pinko C, Matthews DA, Kan CC. Structure of the human cytomegalovirus protease catalytic domain reveals a novel serine protease fold and catalytic triad. Cell. 1996;86:835–843. doi: 10.1016/S0092-8674(00)80157-9. [DOI] [PubMed] [Google Scholar]
  14. Chen Z, Li Y, Clhen E, Hall DL, Darke PL, Culberson C, Shafer JA, Kuo LC. Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases. J Biol Chem. 1994;269:26344–26348. [PubMed] [Google Scholar]
  15. Cicero DO, Barbato G, Koch U, Ingallinella P, Bianchi E, Nardi MC, Steinkuhler C, Cortese R, Matassa V, De Francesco R, Pessi A, Bazzo R. Structural characterization of the interactions of optimized product inhibitors with the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein by NMR and modelling studies. J Mol Biol. 1999;289:385–396. doi: 10.1006/jmbi.1999.2746. [DOI] [PubMed] [Google Scholar]
  16. Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, Wohrmann A, Katlama C, Wilkin T, Haubrich R, Cohen C, Farthing C, Jayaweera D, Markowitz M ,, Ruane P, Guzman Spinosa-S, Lefebvre E. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369:1169–1178. doi: 10.1016/S0140-6736(07)60497-8. [DOI] [PubMed] [Google Scholar]
  17. Colonno R, Rose R, McLaren C, Thiry A, Parkin N, Friborg J. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J Infect Dis. 2004;189:1802–1810. doi: 10.1086/386291. [DOI] [PubMed] [Google Scholar]
  18. Condra JH, Holder DJ, Schleif WA, Blahy OM, Danovich RM, Gabryelski LJ, Graham DJ, Laird D, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, Yang T, Chodakewitz JA, Deutsch PJ, Leavitt RY, Massari FE, Mellors JW, Squires KE, Steigbigel RT, Teppler H, Emini EA. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol. 1996;70:8270–8276. doi: 10.1128/jvi.70.12.8270-8276.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Cottier V, Barberis A, Luthi U. Novel yeast cell-based assay to screen for inhibitors of human cytomegalovirus protease in a high-throughput format. Antimicrob Agents Chemother. 2006;50:565–571. doi: 10.1128/AAC.50.2.565-571.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Craig JC, Duncan IB, Hockley D, Grief C, Roberts NA, Mills JS. Antiviral properties of Ro 31–8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antiviral Res. 1991;16:295–305. doi: 10.1016/0166-3542(91)90045-S. [DOI] [PubMed] [Google Scholar]
  21. Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, Raventos A, Rubio R, Bouza E, Pintado V, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European—Australian Collaborative Ritonavir Study Group. N Engl J Med. 1995;333:1528–1533. doi: 10.1056/NEJM199512073332303. [DOI] [PubMed] [Google Scholar]
  22. Darke PL, Cole JL, Waxman L, Hall DL, Sardana MK, Kuo LC. Active human cytomegalovirus protease is a dimer. J Biol Chem. 1996;271:7445–7449. doi: 10.1074/jbc.271.13.7445. [DOI] [PubMed] [Google Scholar]
  23. De Francesco R, Carfi A. Advances in the development of new therapeutic agents targeting the NS3—4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Adv Drug Deliv Rev. 2007;59:1242–1262. doi: 10.1016/j.addr.2007.04.016. [DOI] [PubMed] [Google Scholar]
  24. DeLano WL. The PyMOL molecular graphics system. DeLano Scientific. CA, USA: Palo Alto; 2002. [Google Scholar]
  25. Dierynck I, De Wit M, Gustin E, Keuleers I, Vandersmissen J, Hallenberger S, Hertogs K. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J Virol. 2007;81:13845–13851. doi: 10.1128/JVI.01184-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Erbel P, Schiering N, Arcy D'A, Renatus M, Kroemer M, Lim SP, Yin Z, Keller TH, Vasudevan SG, Hommel U. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat Struct Mol Biol. 2006;13:372–373. doi: 10.1038/nsmb1073. [DOI] [PubMed] [Google Scholar]
  27. Fear G, Komarnytsky S, Raskin I. Protease inhibitors and their peptidomimetic derivatives as potential drugs. Pharmacol Ther. 2007;113:354–368. doi: 10.1016/j.pharmthera.2006.09.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Forestier N, Reesink HW, Weegink CJ, McNair L, Kieffer TL, Chu HM, Purdy S, Jansen PL, Zeuzem S. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology. 2007;46:640–648. doi: 10.1002/hep.21774. [DOI] [PubMed] [Google Scholar]
  29. Gathe J, Cooper DA, Farthing C, Jayaweera D, Norris D, Pierone G, Jr, Steinhart CR, Trottier B, Walmsley SL, Workman C, Mukwaya G, Kohlbrenner V, Dohnanyi C, McCallister S, Mayers D. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. Clin Infect Dis. 2006;43:1337–1346. doi: 10.1086/508353. [DOI] [PubMed] [Google Scholar]
  30. Goetz DH, Choe Y, Hansell E, Chen YT, McDowell M, Jonsson CB, Roush WR, McKerrow J, Craik CS. Substrate specificity profiling and identification of a new class of inhibitor for the major protease of the SARS coronavirus. Biochemistry. 2007;46:8744–8752. doi: 10.1021/bi0621415. [DOI] [PubMed] [Google Scholar]
  31. de Requena Gonzalez D, Gallego O, Valer L, Jimenez-Nacher I, Soriano V. Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient. AIDS Res Hum Retroviruses. 2004;20:275–278. doi: 10.1089/088922204322996509. [DOI] [PubMed] [Google Scholar]
  32. Hayden FG, Turner RB, Gwaltney JM, Burris Chi-K, Gersten M, Hsyu P, Patick AK, Smith GJ, III, Zalman LS. Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antimicrob Agents Chemother. 2003;47:3907–3916. doi: 10.1128/AAC.47.12.3907-3916.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Hinrichsen H, Benhamou Y, Wedemeyer H, Reiser M, Sentjens RE, Calleja JL, Forns X, Erhardt A, Cronlein J, Chaves RL, Yong CL, Nehmiz G, Steinmann GG. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology. 2004;127:1347–1355. doi: 10.1053/j.gastro.2004.08.002. [DOI] [PubMed] [Google Scholar]
  34. Hoetelmans RM. Pharmacology of antiretroviral drugs. Antivir Ther. 1999;4(Suppl 3):29–41. [PubMed] [Google Scholar]
  35. Hoffman NG, Schiffer CA, Swanstrom R. Covariation of amino acid positions in HIV-1 protease. Virology. 2003;314:536–548. doi: 10.1016/S0042-6822(03)00484-7. [DOI] [PubMed] [Google Scholar]
  36. Hon CC, Lam TY, Shi ZL, Drummond AJ, Yip CW, Zeng F, Lam PY, Leung FC. Evidence of the recombinant origin of a bat severe acute respiratory syndrome (SARS)-like coronavirus and its implications on the direct ancestor of SARS coronavirus. J Virol. 2008;82:1819–1826. doi: 10.1128/JVI.01926-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Ingallinella P, Altamura S, Bianchi E, Taliani M, Ingenito R, Cortese R, De Francesco R, Steinkuhler C, Pessi A. Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products. Biochemistry. 1998;37:8906–8914. doi: 10.1021/bi980314n. [DOI] [PubMed] [Google Scholar]
  38. Jacobsen H, Yasargil K, Winslow DL, Craig JC, Krohn A, Duncan IB, Mous J. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31–8959. Virology. 1995;206:527–534. doi: 10.1016/S0042-6822(95)80069-7. [DOI] [PubMed] [Google Scholar]
  39. Jacobson IM, Everson GT, Gordon SC, Kauffman R, McNair L, Muir A, McHutchison JG (2007) Interim analysis results from a phase 2 study of telaprevir with peginterferon alfa-2A and ribavirin in treatmentnaive subjects with hepatitis C. AASLD 58th Annual Meet, Abstract 177
  40. Johnson M. Response to “Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles?” by Hill. AIDS. 2006;20:1987. doi: 10.1097/01.aids.0000247125.42753.63. [DOI] [PubMed] [Google Scholar]
  41. Johnston E, Winters MA, Rhee SY, Merigan TC, Schiffer CA, Shafer RW. Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance. Antimicrob Agents Chemother. 2004;48:4864–4868. doi: 10.1128/AAC.48.12.4864-4868.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Kempf DJ, Marsh KC, Denissen JF, McDonald E, Vasavanonda S, Flentge CA, Green BE, Fino L, Park CH, Kong XP, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA. 1995;92:2484–2488. doi: 10.1073/pnas.92.7.2484. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Kempf DJ, Marsh KC, Kumar G, Rodrigues AD, Denissen JF, McDonald E, Kukulka MJ, Hsu A, Granneman GR, Baroldi PA, Sun E, Pizzuti D, Plattner JJ, Norbeck DW, Leonard JM. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother. 1997;41:654–660. doi: 10.1128/aac.41.3.654. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Kempf DJ, Isaacson JD, King MS, Brun SC, Xu Y, Real K, Bernstein BM, Japour AJ, Sun E, Rode RA. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol. 2001;75:7462–7469. doi: 10.1128/JVI.75.16.7462-7469.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Khayat R, Batra R, Qian C, Halmos T, Bailey M, Tong L. Structural and biochemical studies of inhibitor binding to human cytomegalovirus protease. Biochemistry. 2003;42:885–891. doi: 10.1021/bi027045s. [DOI] [PubMed] [Google Scholar]
  46. Kim JL, Morgenstern KA, Lin C, Fox T, Dwyer MD, Landro JA, Chambers SP, Markland W, Lepre CA, O'Malley ET, Harbeson SL, Rice CM, Murcko MA, Caron PR, Thomson JA. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell. 1996;87:343–355. doi: 10.1016/S0092-8674(00)81351-3. [DOI] [PubMed] [Google Scholar]
  47. King JR, Wynn H, Brundage R, Acosta EP. Pharmacokinetic enhancement of protease inhibitor therapy. Clin Pharmacokinet. 2004a;43:291–310. doi: 10.2165/00003088-200443050-00003. [DOI] [PubMed] [Google Scholar]
  48. King NM, Prabu-Jeyabalan M, Nalivaika EA, Wigerinck P, de Béthune MP, Schiffer CA. Structural and thermodynamic basis for the binding of TMC114, a nextgeneration human immunodeficiency virus type 1 protease inhibitor. J Virol. 2004b;78:12012–12021. doi: 10.1128/JVI.78.21.12012-12021.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Kitchen VS, Skinner C, Ariyoshi K, Lane EA, Duncan IB, Burckhardt J, Burger HU, Bragman K, Pinching AJ, Weber JN. Safety and activity of saquinavir in HIV infection. Lancet. 1995;345:952–955. doi: 10.1016/S0140-6736(95)90699-1. [DOI] [PubMed] [Google Scholar]
  50. Koh Y, Nakata H, Maeda K, Ogata H, Bilcer G, Devasamudram T, Kincaid JF, Boross P, Wang YF, Tie Y, Volarath P, Gaddis L, Harrison RW, Weber IT, Ghosh AK, Mitsuya H. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother. 2003;47:3123–3129. doi: 10.1128/AAC.47.10.3123-3129.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Krohn A, Redshaw S, Ritchie JC, Graves BJ, Hatada MH. Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. J Med Chem. 1991;34:3340–3342. doi: 10.1021/jm00115a028. [DOI] [PubMed] [Google Scholar]
  52. Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, Bos M, Cameron DR, Cartier M, Cordingley MG, Faucher AM, Goudreau N, Kawai SH, Kukolj G, Lagace L, La-Plante SR, Narjes H, Poupart MA, Rancourt J, Sentjens RE, St George R, Simoneau B, Steinmann G, Thibeault D, Tsantrizos YS, Weldon SM, Yong CL, Llinas-Brunet M. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature. 2003;426:186–189. doi: 10.1038/nature02099. [DOI] [PubMed] [Google Scholar]
  53. Lee TW, Cherney MM, Huitema C, Liu J, James KE, Powers JC, Eltis LD, James MN. Crystal structures of the main peptidase from the SARS coronavirus inhibited by a substratelike aza-peptide epoxide. J Mol Biol. 2005;353:1137–1151. doi: 10.1016/j.jmb.2005.09.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Liang PH. Characterization and inhibition of SARS-coronavirus main protease. Curr Top Med Chem. 2006;6:361–376. doi: 10.2174/156802606776287090. [DOI] [PubMed] [Google Scholar]
  55. Lin C. HCV NS3/4A serine protease. In: Tan SL, editor. Hepatitis C viruses: genomes and molecular biology. Norfolk, UK: Horizon Scientific; 2006. pp. 163–206. [Google Scholar]
  56. Liu FY, Roizman B. The herpes simplex virus 1 gene encoding a protease also contains within its coding domain the gene encoding the more abundant substrate. J Virol. 1991;65:5149–5156. doi: 10.1128/jvi.65.10.5149-5156.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Llinas-Brunet M, Bailey M, Fazal G, Goulet S, Halmos T, Laplante S, Maurice R, Poirier M, Poupart MA, Thibeault D, Wernic D, Lamarre D. Peptide-based inhibitors of the hepatitis C virus serine protease. Bioorg Med Chem Lett. 1998;8:1713–1718. doi: 10.1016/S0960-894X(98)00299-6. [DOI] [PubMed] [Google Scholar]
  58. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science. 1999;285:110–113. doi: 10.1126/science.285.5424.110. [DOI] [PubMed] [Google Scholar]
  59. Love RA, Parge HE, Wickersham JA, Hostomsky Z, Habuka N, Moomaw EW, Adachi T, Hostomska Z. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsinlike fold and a structural zinc binding site. Cell. 1996;87:331–342. doi: 10.1016/S0092-8674(00)81350-1. [DOI] [PubMed] [Google Scholar]
  60. MacManus S, Yates PJ, Elston RC, White S, Richards N, Snowden W. GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks. AIDS. 2004;18:651–655. doi: 10.1097/00002030-200403050-00009. [DOI] [PubMed] [Google Scholar]
  61. Margosiak SA, Vanderpool DL, Sisson W, Pinko C, Kan CC. Dimerization of the human cytomegalovirus protease: kinetic and biochemical characterization of the catalytic homodimer. Biochemistry. 1996;35:5300–5307. doi: 10.1021/bi952842u. [DOI] [PubMed] [Google Scholar]
  62. Markowitz M, Mo H, Kempf DJ, Norbeck DW, Bhat TN, Erickson JW, Ho DD. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol. 1995a;69:701–706. doi: 10.1128/jvi.69.2.701-706.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, Henry D, Sattler F, La Marca A, Leonard JM, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med. 1995b;333:1534–1539. doi: 10.1056/NEJM199512073332304. [DOI] [PubMed] [Google Scholar]
  64. Markowitz M, Conant M, Hurley A, Schluger R, Duran M, Peterkin J, Chapman S, Patick A, Hendricks A, Yuen GJ, Hoskins W, Clendeninn N, Ho DD. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. J Infect Dis. 1998;177:1533–1540. doi: 10.1086/515312. [DOI] [PubMed] [Google Scholar]
  65. Matthews DA, Smith WW, Ferre RA, Condon B, Budahazi G, Sisson W, Villafranca JE, Janson CA, McElroy HE, Gribskov CL, et al. Structure of human rhinovirus 3C protease reveals a trypsin-like polypeptide fold, RNA-binding site, and means for cleaving precursor polyprotein. Cell. 1994;77:761–771. doi: 10.1016/0092-8674(94)90059-0. [DOI] [PubMed] [Google Scholar]
  66. Matthews DA, Dragovich PS, Webber SE, Fuhrman SA, Patick AK, Zalman LS, Hendrickson TF, Love RA, Prins TJ, Marakovits JT, Zhou R, Tikhe J, Ford CE, Meador JW, Ferre RA, Brown EL, Binford SL, Brothers MA, DeLisle DM, Worland ST. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc Natl Acad Sci USA. 1999;96:11000–11007. doi: 10.1073/pnas.96.20.11000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Melino S, Paci M. Progress for dengue virus diseases. Towards the NS2B-NS3pro inhibition for a therapeutic-based approach. FEBS J. 2007;274:2986–3002. doi: 10.1111/j.1742-4658.2007.05831.x. [DOI] [PubMed] [Google Scholar]
  68. Murphy RL, Brun S, Hicks C, Eron JJ, Gulick R, King M, White ACJr, Benson C, Thompson M, Kessler HA, Hammer S, Bertz R, Hsu A, Japour A, Sun E. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS. 2001;15:F1–F9. doi: 10.1097/00002030-200101050-00002. [DOI] [PubMed] [Google Scholar]
  69. Partaledis JA, Yamaguchi K, Tisdale M, Blair EE, Falcione C, Maschera B, Myers RE, Pazhanisamy S, Futer O, Cullinan AB, et al. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J Virol. 1995;69:5228–5235. doi: 10.1128/jvi.69.9.5228-5235.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Patick AK. Rhinovirus chemotherapy. Antiviral Res. 2006;71:391–396. doi: 10.1016/j.antiviral.2006.03.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Patick AK, Brothers MA, Maldonado F, Binford S, Maldonado O, Fuhrman S, Petersen A, Smith GJ, Zalman LS, Burns-Naas LA, Tran JQ. In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother. 2005;49:2267–2275. doi: 10.1128/AAC.49.6.2267-2275.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Pause A, Kukolj G, Bailey M, Brault M, Do F, Halmos T, Lagace L, Maurice R, Marquis M, McKercher G, Pellerin C, Pilote L, Thibeault D, Lamarre D. An NS3 serine protease inhibitor abrogates replication of subgenomic hepatitis C virus RNA. J Biol Chem. 2003;278:20374–20380. doi: 10.1074/jbc.M210785200. [DOI] [PubMed] [Google Scholar]
  73. Perni RB, Almquist SJ, Byrn RA, Chandorkar G, Chaturvedi PR, Courtney LF, Decker CJ, Dinehart K, Gates CA, Harbeson SL, Heiser A, Kalkeri G, Kolaczkowski E, Lin K, Luong YP, Rao BG, Taylor WP, Thomson JA, Tung RD, Wei Y, Kwong AD, Lin C. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3–4A serine protease. Antimicrob Agents Chemother. 2006;50:899–909. doi: 10.1128/AAC.50.3.899-909.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Pettit SC, Everitt LE, Choudhury S, Dunn BM, Kaplan AH. Initial cleavage of the human immunodeficiency virus type 1 GagPol precursor by its activated protease occurs by an intramolecular mechanism. J Virol. 2004;78:8477–8485. doi: 10.1128/JVI.78.16.8477-8485.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Plosker GL, Figgitt DP. Tipranavir. Drugs. 2003;63:1611–1618. doi: 10.2165/00003495-200363150-00009. [DOI] [PubMed] [Google Scholar]
  76. Poon LL, Chu DK, Chan KH, Wong OK, Ellis TM, Leung YH, Lau SK, Woo PC, Suen KY, Yuen KY, Guan Y, Peiris JS. Identification of a novel coronavirus in bats. J Virol. 2005;79:2001–2009. doi: 10.1128/JVI.79.4.2001-2009.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Poppe SM, Slade DE, Chong KT, Hinshaw RR, Pagano PJ, Markowitz M, Ho DD, Mo H, Gorman RR, Dueweke TJ, Thaisrivongs S, Tarpley WG. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother. 1997;41:1058–1063. doi: 10.1128/aac.41.5.1058. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Prabu-Jeyabalan M, Nalivaika E, Schiffer CA. Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure. 2002;10:369–381. doi: 10.1016/S0969-2126(02)00720-7. [DOI] [PubMed] [Google Scholar]
  79. Prabu-Jeyabalan M, King NM, Nalivaika EA, Heile -Snyder G, Cammack N, Schiffer CA. Substrate envelope and drug resistance: crystal structure of RO1 in complex with wild-type human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother. 2006;50:1518–1512. doi: 10.1128/AAC.50.4.1518-1521.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Pulido F, Delgado R, Perez-Valero I, Gonzalez-Garcia J, Miralles P, Arranz A, Hernando A, Arribas JR. Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppression. J Antimicrob Chemother. 2008;61:1359–1361. doi: 10.1093/jac/dkn103. [DOI] [PubMed] [Google Scholar]
  81. Qiu X, Culp JS, DiLella AG, Hellmig B, Hoog SS, Janson CA, Smith WW, Abde -Meguid SS. Unique fold and active site in cytomegalovirus protease. Nature. 1996;383:275–279. doi: 10.1038/383275a0. [DOI] [PubMed] [Google Scholar]
  82. Racaniello VR. Picornaviridae: te viruses and their replication. In: Howley DMKaPM., editor. Fundamental virology. 4th. Philadelphia: Lippincott Williams and Wilkins; 2001. pp. 529–566. [Google Scholar]
  83. Rajagopalan P, Stevens S, Stoceva A, Brandhumber B, Zahang H, Gale M, Blatt LM, Seiwert S, Kossen K (2007) Genotype coverage of the HCV NS3/4A Protease Inhibitor ITMN-191 (R7227): biochemical data reveals potent inhibition and slow dissociation with Genotype 1–6 Proteases. AASLD, Abstract 1386
  84. Randolph JT, De Goey DA. Peptidomimetic inhibitors of HIV protease. Curr Top Med Chem. 2004;4:1079–1095. doi: 10.2174/1568026043388330. [DOI] [PubMed] [Google Scholar]
  85. Reesink HW, Zeuzem S, Weegink CJ, Forestier N, van Vliet A, van de Wetering de Rooij J, McNair L, Purdy S, Kauffman R, Alam J, Jansen PL. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology. 2006;131:997–1002. doi: 10.1053/j.gastro.2006.07.013. [DOI] [PubMed] [Google Scholar]
  86. Reiser M, Hinrichsen H, Benhamou Y, Reesink HW, Wedemeyer H, Avendano C, Riba N, Yong CL, Nehmiz G, Steinmann GG. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology. 2005;41:832–835. doi: 10.1002/hep.20612. [DOI] [PubMed] [Google Scholar]
  87. Rhee SY, Fessel WJ, Zolopa AR, Hurley L, Liu T, Taylor J, Nguyen DP, Slome S, Klein D, Horberg M, Flamm J, Follansbee S, Schapiro JM, Shafer RW. HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. J Infect Dis. 2005;192:456–465. doi: 10.1086/431601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Robinson BS, Riccardi KA, Gong YF, Guo Q, Stock DA, Blair WS, Terry BJ, Deminie CA, Djang F, Colonno RJ, Lin PF. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Chemother. 2000;44:2093–2099. doi: 10.1128/AAC.44.8.2093-2099.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Rodriguez-French A, Boghossian J, Gray GE, Nadler JP, Quinones AR, Sepulveda GE, Millard JM, Wannamaker PG. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J Acquir Immune Defic Syndr. 2004;35:22–32. doi: 10.1097/00126334-200401010-00003. [DOI] [PubMed] [Google Scholar]
  90. Rusconi S, La Seta Catamancio S, Citterio P, Kurtagic S, Violin M, Balotta C, Moroni M, Galli M, d'ArminioMonforte A. Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob Agents Chemother. 2000;44:1328–1332. doi: 10.1128/AAC.44.5.1328-1332.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Sanne I, Piliero P, Squires K, Thiry A, Schnittman S. Results of a phase 2 clinical trial at 48 weeks (AI424–007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr. 2003;32:18–29. doi: 10.1097/00126334-200301010-00004. [DOI] [PubMed] [Google Scholar]
  92. Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey D, Gupta SK, Hussain M, Shah A, Cutler D, Zhang J, Zeuzem S. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology. 2007;132:1270–1278. doi: 10.1053/j.gastro.2007.01.041. [DOI] [PubMed] [Google Scholar]
  93. Sham HL, Kempf DJ, Molla A, Marsh KC, Kumar GN, Chen CM, Kati W, Stewart K, Lal R, Hsu A, Betebenner D, Korneyeva M, Vasavanonda S, McDonald E, Saldivar A, Wideburg N, Chen X, Niu P, Park C, Jayanti V, Grabowski B, Granneman GR, Sun E, Japour AJ, Leonard JM, Plattner JJ, Norbeck DW. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother. 1998;42:3218–3224. doi: 10.1128/aac.42.12.3218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Shieh HS, Kurumbail RG, Stevens AM, Stegeman RA, Sturman EJ, Pak JY, Wittwer AJ, Palmier MO, Wiegand RC, Holwerda BC, Stallings WC. Three-dimensional structure of human cytomegalovirus protease. Nature. 1996;383:279–282. doi: 10.1038/383279a0. [DOI] [PubMed] [Google Scholar]
  95. Shimba N, Nomura AM, Marnett AB, Craik CS. Herpesvirus protease inhibition by dimer disruption. J Virol. 2004;78:6657–6665. doi: 10.1128/JVI.78.12.6657-6665.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  96. Simmen K, Lenz O, Lin T, Fanning G, Raboisson P, de Kock H, van ‘t Klooster G, Rosenquist A, Edlund M, Nilsson M, Vrang L, Samuelsson B (2007) In vitro and preclinical pharmacokinetics of the HCV protease inhibitor, TMC435350. AASLD, Abstract 1390
  97. Squires K, Lazzarin A, Gatell JM, Powderly WG, Pokrovskiy V, Delfraissy JF, Jemsek J, Rivero A, Rozenbaum W, Schrader S, Sension M, Vibhagool A, Thiry A, Giordano M. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr. 2004;36:1011–1019. doi: 10.1097/00126334-200408150-00003. [DOI] [PubMed] [Google Scholar]
  98. St Clair MH, Millard J, Rooney J, Tisdale M, Parry N, Sadler BM, Blum MR, Painter G. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. Antiviral Res. 1996;29:53–56. doi: 10.1016/0166-3542(95)00916-7. [DOI] [PubMed] [Google Scholar]
  99. Stein DS, Fish DG, Bilello JA, Preston SL, Martineau GL, Drusano GL. A 24-week openlabel phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir) AIDS. 1996;10:485–492. doi: 10.1097/00002030-199605000-00006. [DOI] [PubMed] [Google Scholar]
  100. Steinkuhler C, Urbani A, Tomei L, Biasiol G, Sardana M, Bianchi E, Pessi A, De Francesco R. Activity of purified hepatitis C virus protease NS3 on peptide substrates. J Virol. 1996;70:6694–6700. doi: 10.1128/jvi.70.10.6694-6700.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  101. Steinkuhler C, Biasiol G, Brunetti M, Urbani A, Koch U, Cortese R, Pessi A, De Francesco R. Product inhibition of the hepatitis C virus NS3 protease. Biochemistry. 1998;37:8899–8905. doi: 10.1021/bi980313v. [DOI] [PubMed] [Google Scholar]
  102. Stoll V, Qin W, Stewart KD, Jakob C, Park C, Walter K, Simmer RL, Helfrich R, Bussiere D, Kao J, Kempf D, Sham HL, Norbeck DW. X-ray crystallographic structure of ABT-378 (lopinavir) bound to HIV-1 protease. Bioorg Med Chem. 2002;10:2803–2806. doi: 10.1016/S0968-0896(02)00051-2. [DOI] [PubMed] [Google Scholar]
  103. Swanstrom R, Wills JW. Synthesis, assembly, and processing of viral proteins. In: Coffin JM, Hughes SH, Varmus HE, editors. Retroviruses. Cold Spring Harbor Laboratory. NY: Cold Spring Harbor; 1997. pp. 263–334. [PubMed] [Google Scholar]
  104. Thaisrivongs S, Strohbach JW. Structure-based discovery of Tipranavir disodium (PNU-140690E): a potent, orally bioavailable, nonpeptidic HIV protease inhibitor. Biopolymers. 1999;51:51–58. doi: 10.1002/(SICI)1097-0282(1999)51:1<51::AID-BIP6>3.0.CO;2-U. [DOI] [PubMed] [Google Scholar]
  105. Tong L. Viral proteases. Chem Rev. 2002;102:4609–4626. doi: 10.1021/cr010184f. [DOI] [PubMed] [Google Scholar]
  106. Tong L, Qian C, Massariol MJ, Bonneau PR, Cordingley MG, Lagace L. A new serineprotease fold revealed by the crystal structure of human cytomegalovirus protease. Nature. 1996;383:272–275. doi: 10.1038/383272a0. [DOI] [PubMed] [Google Scholar]
  107. Tong L, Qian C, Massariol MJ, Deziel R, Yoakim C, Lagace L. Conserved mode of peptidomimetic inhibition and substrate recognition of human cytomegalovirus protease. Nat Struct Biol. 1998;5:819–826. doi: 10.1038/1860. [DOI] [PubMed] [Google Scholar]
  108. Turriziani O, Antonelli G, Jacobsen H, Mous J, Riva E, Pistello M, Dianzani F. Identification of an amino acid substitution involved in the reduction of sensitivity of HIV-1 to an inhibitor of viral proteinase. Acta Virol. 1994;38:297–298. [PubMed] [Google Scholar]
  109. Vacca JP, Dorsey BD, Schleif WA, Levin RB, McDaniel SL, Darke PL, Zugay J, Quintero JC, Blahy OM, Roth E, et al. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci USA. 1994;91:4096–4100. doi: 10.1073/pnas.91.9.4096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  110. Venkatraman S, Bogen SL, Arasappan A, Bennett F, Chen K, Jao E, Liu YT, Lovey R, Hendrata S, Huang Y, Pan W, Parekh T, Pinto P, Popov V, Pike R, Ruan S, Santhanam B, Vibulbhan B, Wu W, Yang W, Kong J, Liang X, Wong J, Liu R, Butkiewicz N, Chase R, Hart A, Agrawal S, Ingravallo P, Pichardo J, Kong R, Baroudy B, Malcolm B, Guo Z, Prongay A, Madison V, Broske L, Cui X, Cheng KC, Hsieh Y, Brisson JM, Prelusky D, Korfmacher W, White R, Bogdanowich-Knipp S, Pavlovsky A, Bradley P, Saksena AK, Ganguly A, Piwinski J, Girijaval-labhan V, Njoroge FG. Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1- oxobuty l]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. J Med Chem. 2006;49:6074–6086. doi: 10.1021/jm060325b. [DOI] [PubMed] [Google Scholar]
  111. Welch AR, Woods AS, McNally LM, Cotter RJ, Gibson W. A herpesvirus maturational proteinase, assemblin: identification of its gene, putative active site domain, and cleavage site. Proc Natl Acad Sci USA. 1991;88:10792–10796. doi: 10.1073/pnas.88.23.10792. [DOI] [PMC free article] [PubMed] [Google Scholar]
  112. Wlodawer A, Erickson JW. Structure-based inhibitors of HIV-1 protease. Annu Rev Biochem. 1993;62:543–585. doi: 10.1146/annurev.bi.62.070193.002551. [DOI] [PubMed] [Google Scholar]
  113. Wu TD, Schiffer CA, Gonzales MJ, Taylor J, Kantor R, Chou S, Israelski D, Zolopa AR, Fessel WJ, Shafer RW. Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J Virol. 2003;77:4836–4847. doi: 10.1128/JVI.77.8.4836-4847.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  114. Wyles DL, Kaihara KA, Vaida F, Schooley RT. Synergy of small molecular inhibitors of hepatitis C virus replication directed at multiple viral targets. J Virol. 2007;81:3005–3008. doi: 10.1128/JVI.02083-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  115. Xue X, Yu H, Yang H, Xue F, Wu Z, Shen W, Li J, Zhou Z, Ding Y, Zhao Q, Zhang XC, Liao M, Bartlam M, Rao Z. Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design. J Virol. 2008;82:2515–2527. doi: 10.1128/JVI.02114-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  116. Yang H, Yang M, Ding Y, Liu Y, Lou Z, Zhou Z, Sun L, Mo L, Ye S, Pang H, Gao GF, Anand K, Bartlam M, Hilgenfeld R, Rao Z. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc Natl Acad Sci USA. 2003;100:13190–13195. doi: 10.1073/pnas.1835675100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  117. Yang H, Xie W, Xue X, Yang K, Ma J, Liang W, Zhao Q, Zhou Z, Pei D, Ziebuhr J, Hilgenfeld R, Yuen KY, Wong L, Gao G, Chen S, Chen Z, Ma D, Bartlam M, Rao Z. Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol. 2005;3:e324. doi: 10.1371/journal.pbio.0030324. [DOI] [PMC free article] [PubMed] [Google Scholar]
  118. Yang S, Chen SJ, Hsu MF, Wu JD, Tseng CT, Liu YF, Chen HC, Kuo CW, Wu CS, Chang LW, Chen WC, Liao SY, Chang TY, Hung HH, Shr HL, Liu CY, Huang YA, Chang LY, Hsu JC, Peters CJ, Wang AH, Hsu MC. Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor. J Med Chem. 2006;49:4971–4980. doi: 10.1021/jm0603926. [DOI] [PubMed] [Google Scholar]
  119. Yao N, Reichert P, Taremi SS, Prosise WW, Weber PC. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional proteasehelicase. Structure. 1999;7:1353–1363. doi: 10.1016/S0969-2126(00)80025-8. [DOI] [PubMed] [Google Scholar]
  120. Yin J, Niu C, Cherney MM, Zhang J, Huitema C, Eltis LD, Vederas JC, James MN. A mechanistic view of enzyme inhibition and peptide hydrolysis in the active site of the SARS-CoV 3C-like peptidase. J Mol Biol. 2007;371:1060–1074. doi: 10.1016/j.jmb.2007.06.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  121. Yusof R, Clum S, Wetzel M, Murthy HM, Padmanabhan R. Purified NS2B/NS3 serine protease of dengue virus type 2 exhibits cofactor NS2B dependence for cleavage of substrates with dibasic amino acids in vitro. J Biol Chem. 2000;275:9963–9969. doi: 10.1074/jbc.275.14.9963. [DOI] [PubMed] [Google Scholar]
  122. Zeuzem S, Hezode C, Ferenci P, Dusheiko GM, Pol S, Goeser T, Bronowicki J, Gharakhanian S, Devonish D, Kauffman R, Alam J, Pawlotsky J (2007) PROVE2: phase II study of VX950 (telaprevir) in combination with peginterferon ALFA2A with or without ribavirin in subjects with chronic hepatitis C, first interim analysis. AASLD, Abstract 80
  123. Zhang R, Durkin J, Windsor WT, McNemar C, Ramanathan L, Le HV. Probing the substrate specificity of hepatitis C virus NS3 serine protease by using synthetic peptides. J Virol. 1997;71:6208–6213. doi: 10.1128/jvi.71.8.6208-6213.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antiviral Strategies are provided here courtesy of Nature Publishing Group

RESOURCES